Research programme: T-cell therapies - TCR2 Therapeutics

Drug Profile

Research programme: T-cell therapies - TCR2 Therapeutics

Alternative Names: TC 210; TCR fusion construct T-cell therapies - TCR2 Therapeutics; TRuC™ T-cells

Latest Information Update: 22 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TCR2 Therapeutics
  • Developer Ludwig-Maximilians-University; Massachusetts General Hospital; TCR2 Therapeutics; University of Freiburg
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 13 Jun 2017 Preclinical trials in Haematological malignancies in USA (Parenteral)
  • 13 Jun 2017 Pharmacodynamics data from preclinical trials in Solid tumours released by TCR2 therapeutics
  • 13 Jun 2017 TCR2 Therapeutics plans a clinical trial of TC 210 for Solid tumours in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top